Sanofi (F:SNW2) — Stock Price
Sanofi (F:SNW2) is currently trading at €37.40 EUR, down 0.53% today. Over the past 52 weeks, shares have ranged between €35.60 and €45.00. This page tracks Sanofi's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market cap of Sanofi.
Sanofi (SNW2) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Sanofi's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
Sanofi Income Statement — Revenue, Profit & Earnings by Year
Sanofi's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | €44.29 Billion | €41.62 Billion | €45.39 Billion | €39.17 Billion | €37.37 Billion |
| Cost of Revenue | €13.21 Billion | €12.63 Billion | €13.70 Billion | €12.26 Billion | €12.16 Billion |
| Gross Profit | €31.08 Billion | €28.99 Billion | €31.69 Billion | €26.92 Billion | €25.21 Billion |
| Research & Development | €7.39 Billion | €6.51 Billion | €6.71 Billion | €5.69 Billion | €5.53 Billion |
| SG&A | €9.18 Billion | €8.93 Billion | €10.49 Billion | €9.55 Billion | €9.39 Billion |
| Total Operating Expenses | €34.82 Billion | €32.44 Billion | €33.51 Billion | €30.03 Billion | €29.48 Billion |
| Operating Income | €9.46 Billion | €9.18 Billion | €11.88 Billion | €9.15 Billion | €7.89 Billion |
| EBITDA | — | — | €10.76 Billion | €9.75 Billion | €17.92 Billion |
| EBIT | — | — | €11.04 Billion | €8.56 Billion | €7.58 Billion |
| Interest Expense | €749.00 Million | €710.00 Million | €440.00 Million | €403.00 Million | €436.00 Million |
| Income Before Tax | €6.70 Billion | €6.25 Billion | €8.27 Billion | €7.80 Billion | €13.80 Billion |
| Income Tax Expense | — | — | €2.01 Billion | €1.56 Billion | €1.81 Billion |
| Net Income | €5.56 Billion | €5.40 Billion | €6.72 Billion | €6.22 Billion | €12.31 Billion |
Sanofi Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Sanofi's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | €132.80 Billion | €126.46 Billion | €124.58 Billion | €120.24 Billion | €114.53 Billion |
| Total Current Assets | €42.59 Billion | €30.67 Billion | €34.11 Billion | €30.65 Billion | €33.79 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | €486.00 Million | €270.00 Million | €664.00 Million | €1.05 Billion | €900.00 Million |
| Net Receivables | €7.68 Billion | €8.43 Billion | €8.42 Billion | €7.57 Billion | €7.57 Billion |
| Inventory | €9.43 Billion | €9.67 Billion | €8.96 Billion | €8.71 Billion | €8.35 Billion |
| Property, Plant & Equipment | — | — | €11.68 Billion | €11.98 Billion | €10.56 Billion |
| Goodwill | €43.38 Billion | €49.40 Billion | €49.89 Billion | €48.06 Billion | €44.36 Billion |
| Total Liabilities | €54.94 Billion | €52.11 Billion | €51.07 Billion | €51.21 Billion | €51.38 Billion |
| Total Current Liabilities | €29.16 Billion | €24.21 Billion | €23.97 Billion | €21.30 Billion | €19.28 Billion |
| Long-term Debt | €11.79 Billion | €14.35 Billion | €14.86 Billion | €17.12 Billion | €19.75 Billion |
| Net Debt | €8.56 Billion | €7.68 Billion | €6.29 Billion | €10.21 Billion | €8.60 Billion |
| Total Stockholder Equity | €77.51 Billion | €74.04 Billion | €73.14 Billion | €68.68 Billion | €63.00 Billion |
| Retained Earnings | — | — | — | — | — |
Sanofi Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Sanofi generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | €9.08 Billion | €10.26 Billion | €10.53 Billion | €10.52 Billion | €7.42 Billion |
| Capital Expenditures | €3.19 Billion | €3.02 Billion | €1.61 Billion | €1.48 Billion | €1.25 Billion |
| Free Cash Flow | €5.89 Billion | €7.23 Billion | €8.32 Billion | €8.48 Billion | €5.33 Billion |
| Investing Cash Flow | — | — | €-2.08 Billion | €-7.30 Billion | €3.62 Billion |
| Financing Cash Flow | €-5.75 Billion | €-8.05 Billion | €-5.82 Billion | €-7.06 Billion | €-6.49 Billion |
| Dividends Paid | €4.70 Billion | €4.45 Billion | €4.17 Billion | €4.01 Billion | €3.94 Billion |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | €3.59 Billion | €4.79 Billion | €3.37 Billion | €3.00 Billion | €3.19 Billion |
| Change in Cash | €-1.27 Billion | €-4.03 Billion | €2.64 Billion | €-3.82 Billion | €4.49 Billion |
Sanofi Earnings History — EPS Actual vs. Analyst Estimates
Track Sanofi's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 22, 2026 | — | — | — |
| Jan 29, 2026 | — | 0.80 | — |
| Oct 24, 2025 | — | — | — |
| Jul 31, 2025 | — | — | — |
| Apr 24, 2025 | — | — | — |
| Jun 30, 2021 | 0.83 | 0.75 | +10.67% |
| Mar 31, 2021 | 0.97 | 0.78 | +24.36% |
| Dec 31, 2020 | 0.73 | 0.69 | +5.80% |